Stay updated with breaking news from Thomask Equels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
OCALA, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the second quarter ended June 30, 2021 and provides a business update. Second
.jpg)
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
/PRNewswire/ -- BioFlorida has announced five new board members who will support the organization's effort to grow the life sciences industry in Florida. "The...
Home / Top News / AIM ImmunoTech Announces Two Year Extension of Agreement with Shenzhen Smoore Technology Limited to Develop and Test a New Inhalation Delivery Device for Ampligen AIM ImmunoTech Announces Two Year Extension of Agreement with Shenzhen Smoore Technology Limited to Develop and Test a New Inhalation Delivery Device for Ampligen Announces plans to conduct Phase 1/2 clinical study incorporating new inhalation technology if the preliminary results of the testing are positive OCALA, Fla., May 27, 2021 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that...
On AIM ImmunoTech Inc. (the "Company") posted an interview of Thomas K. Equels, its president and CEO, to the Company's website. To view this interview, please go to https://aimimmuno.com/FiresideChat050321, where you will find the video and cautionary statements about the interview. The Company announced the interview in a May 3, 2021 press release, a copy of which is furnished herewith as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1, is "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or o...